Click here to view online. Add this email to your safelist.
AstraZeneca’s CVD-REAL study shows SGLT-2 inhibitors significantly reduced death and hospitalisations for heart failure versus other type-2 diabetes medicines
19 March 2017
Landmark real-world evidence from an international study of more than 300,000 patients with type-2 diabetes showed treatment with SGLT-2 inhibitors reduced all-cause mortality by 51% and risk of hospitalisation for heart failure by 39% CVD-REAL data are presented at the American College of Cardiology 66th Annual Scientific Session
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
